Clinical trial · Observational
Thyroid Dysfunction and Nivolumab Reponse in NSCLC
Thyroid Biological Toxicity and Tumor Response in Patients Treated With NIVOLUMAB 2nd Line in Non-small Cell Bronchopulmonary Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational, retrospective and monocentric study, conducted at the university Hospital of Brest The primary objective is to assess the association between the occurrence of thyroid dysfunction in patients treated with Nivolumab® for a non-small cell lung cancer and prognosis and therapeutic response The second objective is to assess prognosis and therapeutic response according to severity and subtype of thyroid dysfunction
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Immune Checkpoint Inhibitor | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer Metastatic | — | UNRESOLVED | — |
| Prognosis | — | UNRESOLVED | — |
| Thyroid Dysfunction | — | UNRESOLVED | — |
| Treatment Adverse Effect | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- overall survival
- timeFrame
- up to 48 months
- description
- OS was defined as the time between the introduction of Nivolumab® and death
Secondary outcomes (3)
- measure
- objective response rate (ORR)
- timeFrame
- up to 48 months
- description
- The ORR was defined as a partial or complete response
- measure
- disease control rate (DCR)
- timeFrame
- up to 48 months
- description
- DCR was defined as stability or as an objective response
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients at least 18 years old and had histologically confirmed locally advanced stage (IIIB) or metastatic (IV) non-small cell lung cancer with disease progression; * treated with Nivolumab® as second or more therapeutic line * in the oncologic department university hospital of Brest * during the inclusion period between July 20, 2015 to June 30, 2018. Exclusion Criteria: * patients whose primary tumor was not from bronchopulmonary origin * patients with a history of total thyroidectomy and/or having previously treated with levothyroxine and/or having a thyroid dysfunction previously to the introduction of Nivolumab® * patients not having any thyroid monitoring during Nivolumab® treatment, and those for which data were missing * patients who expressed their opposition to participate in the study
References
Publications (0)
Data not yet available